Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "Knee Osteoarthritis (OA)"

Pain Treatments Move Closer to U.S. Market

Michele B. Kaufman, PharmD, BCGP  |  October 18, 2017

Two pain treatments, extended-release injectable suspension triamcinolone acetonide (Zilretta) and meloxicam, have seen movement at the U.S. Food and Drug Administration (FDA). In October, the agency approved Zilretta to treat osteoarthritis (OA) knee pain and accepted a new drug application for meloxicam to treat pain. FDA Approves Zilretta On Oct. 6, the FDA approved extended-release,…

Sleep Therapy May Help Ease Knee Pain

Lisa Rapaport  |  August 16, 2017

(Reuters Health)—Patients with knee osteoarthritis (OA) and insomnia may be less troubled by joint pain after they get treatment to help them sleep better, a recent study suggests. Knee OA, a leading cause of pain and disability in older adults, occurs when flexible tissue at the ends of bones wears down. Although it can’t be…

Online Risk Calculator for Knee OA Influences Patient Risk Perception

Arthritis Care & Research  |  August 1, 2017

A new tool for assessing the risk of developing knee osteoarthritis (OA) may be useful for knee OA education. A recent study found the online risk calculator, OA Risk C, was effective in helping patients better understand their personal risk of developing the disease. It may also motivate some patients to embrace exercise-related behavior changes…

News Updates for Diclofenac Sodium, Denosumab & Sarilumab

Michele B. Kaufman, PharmD, BCGP  |  June 20, 2017

In drug news, a generic 2% diclofenac sodium solution is now available, denosumab is promising to treat osteoporosis, and the FDA has approved sarilumab to treat adults with RA…

Does Chondroitin Trump Celecoxib for Arthritic Knee Pain?

Marilynn Larkin  |  June 8, 2017

(Reuters Health)—A daily supplement of pharmaceutical grade chondroitin is as good as celecoxib (Celebrex) at relieving arthritic knee pain and doesn’t have dangerous side effects, researchers say. Dr. Jean-Yves Reginster of Liege State University in Belgium and colleagues recruited 604 people over age 50 with knee osteoarthritis (OA) from five European countries and randomly assigned…

Review Finds Increased Osteoarthritis Risk in Tactical Athletes

Anne Harding  |  February 14, 2017

NEW YORK (Reuters Health)—Members of the military and firefighters are at increased risk of osteoarthritis (OA), a new systematic review shows. “Osteoarthritis is more common in people who are tactical athletes, people who are firefighters and military service members, than it is in the general population,” Dr. Kenneth Cameron of Keller Army Hospital in West…

FDA Update: FX006 Promising for Knee OA; Pioglitazone Linked to Bladder Cancer Risk; & HIV Drug Gets New Labeling

Michele B. Kaufman, PharmD, BCGP  |  January 4, 2017

The makers of FX006, a steroid injection for treating pain in patients with knee osteoarthritis, have submitted a new drug application to the FDA…

Does Telephone Coaching Enhance Physical Activity Programs?

Arthritis Care & Research  |  January 3, 2017

Health coaching by telephone is increasingly being used to assist in chronic disease self-management. A recent study examined the benefits of simultaneous health coaching via telephone as an addition to a physiotherapist-prescribed home-based physical activity program for patients with knee OA. Although participants receiving additional coaching had a short-term improvement in adherence, changes in pain and function did not differ between the study’s groups at six months…

Low Levels of Vitamin D3 May Increase OA Pain

Lara C. Pullen, PhD  |  December 20, 2016

In a study of patients with knee osteoarthritis (OA), researchers found that the cytokine IL-17A may play a role in the pain associated with the disease. Specifically, decreased serum levels of vitamin D3 may contribute to OA pain via the regulation of immune responses…

New Insights into the Structure of Collagen Fibril

Lara C. Pullen, PhD  |  December 5, 2016

A study of knee and hip articular cartilage found that thick fibers were bundles of thin fibrils—like a multi-thread rope in which each thread corresponds to a prototypic sub-fibril. The organization of the fibers also differed between the cartilages of distinct tissues, which may explain how a breakdown in the fiber pattern contributes to pathology…

  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences